Pharmacogenetic markers of antipsychotic-induced weight gain: leptin and neuroepeptide Y

Antipsychotic drugs are a critical modality in managing of schizophrenia. Although medications can be highly effective, response varies and some patients derive considerably less benefit than others. Long-term use of antipsychotic drugs is associated with the development of adverse reactions. Te safety advantages of the atypical drugs havebeen questioned because of their propensity to induce weight gain and alter glucose and lipid metabolism. Antipsychotic-induced weight gain is a common cause of self-discontinuation of treatment and a significant deterioration in the quality of life in patients with schizophrenia. Te severity of adverse reactions when taking antipsychotics in different patients varies, which be associated with genetic factors. Antipsychotic induced weight gain is a major health concern and unfortunately, there is no predictive tool to identify who are high risk individuals. Te LEP, LEPR and NRY genes represents a compellings candidates for genetic studies of antipsychotic-induced weight gain. Candidate gene selection should rely on current knowledge on the molecular pathways to weight gain, antipsychotic pharmacokinetics and pharmacodynamics, as well as possible disease-related genetic links to the side effects under study. Pharmacogenetics will provide rational treatment based on matching antipsychotics to a patient’s DNA profile, thus, potentially providing effective treatment with minimal side effects to outliers and mean responders to a given antipsychotic medication.

1. Dobrodeeva VS, Tolmachev MY, Shnayder NA, Neznanov NG, Nasyrova RF. Influence of Single Nucleotide Variation of Gene LEP (rs3828942) on Antipsychotic-Induced Abnormal Glucose Metabolism in Patients with Schizophrenia. Sovremennaya terapiya psihicheskih rasstrojstv. 2020; 1:16-20. (In Russ.). doi:10.21265/PSYPH.2020.37.30.002

2. Klinicheskaya psihofarmakogenetika pod red. R.F. Nasyrovoj, N.G. Neznanova.— SPb: Izdatel’stvo DEAN. 2019:405. (In Russ.).

3. Nasyrova RF, Sivakova NA, Ivashhenko DV, Sosin DN, Ershov EE, Sosina KA, Akhmetova LSh, Volikova OV, Bejbalaeva TZ, Neznanov NG. Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art. Obozrenie psikhiatrii i mediczinskoj psikhologii imeni V.M.Bekhtereva. 2016; 3:67-80. (In Russ.).

4. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity— A review. Neuropeptides. 2006; 40(6):375–401. doi:10.1016/j.npep.2006.07.001

5. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatrica Scandinavica. 1999; 100(1):3–16. doi:10.1111/j.1600-0447.1999.tb10908.x

6. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera, et al. Lithium and Body Weight Gain. Pharmacopsychiatry. 1995; 28(02):35–44. doi:10.1055/s-2007-979586

7. Blackburn GL. Blackburn Weight gain and antipsychotic medication. Journal of Clinical Psychiatry. 2000; 61(8):36-41. PMID: 10811242.

8. Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TAP., Kitzrow W, et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012; 38(2):134–141. doi:10.1016/j.pnpbp.2012.03.001

9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. New England Journal of Medicine. 2003; 348(17):1625–1638. doi:10.1056/nejmoa021423

10. Dickerson FB, Brown CH, Kreyenbulh JA, Fang L, Goldberg RW, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006; 113(4):306–313. doi:10.1111/j.1600-0447.2005.00637.x.

11. Dietz WH. Childhood Weight Affects Adult Morbidity and Mortality. The Journal of Nutrition. 1998; 128(2):411–414. doi:10.1093/jn/128.2.411s

12. Ebenbichler C, Laimer M, Kranebitter M, Lechleitner M, Patsch JR., et al. The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophrenia Research. 2005; 75(1):143–146. doi:10.1016/j.schres.2004.10.012

13. Eli Lilly & Company. Zyprexa (Olanzapine). Lilly Laboratory Monograph. Caracas, Venezuela: Eli Lilly & Company. 1996:71-72.

14. Friedman J, Halaas J. Leptin and the regulation of body weight in mammals. Nature. 1998; 395: 763–770. https://doi.org/10.1038/27376

15. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutrition Reviews. 2002; 60(10):1-14. doi:10.1301/002966402320634878

16. Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, & Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology-Endocrinology and Metabolism. 2001; 280(6):827–847. doi:10.1152/ajpendo.2001.280.6.e827

17. Gilpin NW. Corticotropin-releasing factor (CRF) and neuropeptide Y (NPY): Effects on inhibitory transmission in central amygdala, and anxiety& alcohol-related behaviors. Alcohol. 2012; 46(4):329–337. doi:10.1016/j.alcohol.2011.11.009

18. Gopalaswamy AK., Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatrica Scandinavica. 1985; 72(3):254–258. doi:10.1111/j.1600-0447.1985.tb02603.x

19. Gordon HL. Weight Change During and After Hospital Treatment. Archives of General Psychiatry. 1964; 10(2):187. doi:10.1001/archpsyc.1964.01720200083012

20. Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER. Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication. Psychiatric Genetics. 2010; 20(6):311–316. doi:10.1097/ypg.0b013e32833b6378

21. Gregoor JG, van der Weide J, Mulder H, Cohen D, van Megen HJGM, et al. Polymorphisms of the LEPand LEPR Gene and Obesity in Patients Using Antipsychotic Medication. Journal of Clinical Psychopharmacology. 2009; 29(1):21–25. doi:10.1097/jcp.0b013e31819359be

22. Halaas JL, Gajiwala KS, Maffei M, Cohen S, Chair B, et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science. 1995; 269(5223):543–546. doi:10.1126/science.7624777

23. Hales СМ, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults : United States, 2017–2018. NCHS Data Brief. 2020; 360:1-8. PMID: 32487284

24. Haupt DW. Differential metabolic effects of antipsychotic treatments. European Neuropsychopharmacology. 2006; 16:149–155. doi:10.1016/j.euroneuro.2006.06.003

25. Hebebrand J, Blum WF, Barth N, Coners H, Englaro P, et al. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Molecular Psychiatry. 1997; 2(4):330–334. doi:10.1038/sj.mp.4000282

26. Jalenques I, Tauveron I, Albuisson E, Audy V, Fleury-Duhamel N, Coudert A-J. Weight Gain as a Predictor of Long Term Clozapine Efficacy. Clinical Drug Investigation. 1996; 12(1):16–25. doi:10.2165/00044011-199612010-00003

27. Klemettilä JP, Kampman O, Seppälä N, Viikki M, Hämäläinen M., et al. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. European Psychiatry. 2015; 30(2):296-302. doi:10.1016/j.eurpsy.2014.08.006

28. Klett CJ, Caffey EM. Weight changes during treatment with phenothiazine derivatives. Journal of Neuropsychiatry. 1960; 2:102-108. PMID: 13756782.

29. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. The American Journal of Medicine. 2001; 111(9):716–723. doi:10.1016/s0002-9343(01)01000-2

30. Kraus T, Haack M, Schuld A, Hinzw-Selch D, Kuhn M, et al. Body weight and leptinplasmalevels during treatment with antipsychotic drugs. The American journal of psychiatry. 1999; 156(2):312–314. doi:10.1176/ajp.156.2.312

31. Lamberti JS, Bellnier T, Schwarkopz SB. Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry. 1992; 149(5):689–690. doi:10.1176/ajp.149.5.689

32. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine. 2005; 353(12):1209– 1223. doi:10.1056/nejmoa051688

33. Mammes O, Betoulle D, Aubert R, Herbeth B, Siest G, Fumeron F. Association of the G-2548A polymorphism in the 50 region of the LEP gene with overweight. Annals of Human Genetics. 2000; 64(5):391–394. doi:10.1017/s0003480000008277

34. Mantzoros CS. The Role of Leptin in Human Obesity and Disease: A Review of Current Evidence. Annals of Internal Medicine. 1999; 130(8):671. doi:10.7326/0003-4819-130-8-199904200-00014S.

35. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted Disruption of Histamine H1-Receptor Attenuates Regulatory Effects of Leptin on Feeding, Adiposity, and UCP Family in Mice. Diabetes. 2001; 50(2):385–391. doi:10.2337/diabetes.50.2.385

36. Matsuzawa Y. Adiponectin and Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24(1):29–33. doi:10.1161/01.atv.0000099786.99623.ef

37. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics. European Archives of Psychiatry and Clinical Neuroscience. 2005; 255(3):190–201. doi:10.1007/s00406-005-0587-5

38. Nemeroff CB. Dosing the antipsychotic medication olanzapine. The Journal of clinical psychiatry. 1997; 58(10):45–49. PMID: 9265916.

39. Newcomer JW. Second-Generation (Atypical) Antipsychotics and Metabolic Effects. CNS Drugs. 2005; 19 (1):1-93. doi:10.2165/00023210-200519001-00001

40. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophrenia Research. 2010; 121(1-3):199–202. doi:10.1016/j.schres.2010.05.010

41. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica. 1997; 96(4):265–273. doi:10.1111/j.1600-0447.1997.tb10162.x

42. Puangpetch A, Srisawasdi P, Unaharassamee W, Jiratjintana N, Vanavanan S, et al. Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone or clozapine-induced hyperglycemia. Pharmgenomics Pers Med. 2019; 12:155-166. doi:10.2147/PGPM.S210770

43. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacology and Therapeutic. 2010; 125(1):169–179. doi:10.1016/j.pharmthera.2009.10.010

44. Reynolds GP, Yevtushenko OO, Gordon S, Arranz B, San L, Cooper SJ. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. The International Journal of Neuropsychopharmacology. 2012; 16(06):1421– 1425. doi:10.1017/s1461145712001435

45. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the Promoter Region of the Serotonin 5-HT2C Receptor Gene and Clozapine-Induced Weight Gain. American Journal of Psychiatry. 2003; 160(4):677– 679. doi:10.1176/appi.ajp.160.4.677

46. Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. Journal of Psychiatric Research. 1975; 12(1):59–68. doi:10.1016/0022-3956(75)90021-7

47. Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, et al. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics. 2014; 15(4):477–485. doi:10.2217/pgs.13.220

48. Rohner-Jeanrenaud F, Jeanrenaud B. (1996). Obesity, Leptin, and the Brain. New England Journal of Medicine. 1996; 334(5):324–325. doi:10.1056/nejm199602013340511

49. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics. 2005; 15(4):195–200. doi:10.1097/01213011-200504000-00002

50. Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, et al. Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. Journal of Clinical Psychopharmacology. 2013; 33(1):11–17. doi:10.1097/jcp.0b013e31827d145a

51. Van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin. Endocrine Reviews. 2004; 25(3): 426–457. doi:10.1210/er.2002-0029

52. Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. European Journal of Clinical Nutrition. 2010; 64(10): 1043–1051. doi:10.1038/ejcn.2010.114

53. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. The Journal of clinical psychiatry. 2004; 65(18):13-26. PMID: 15600381.

54. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, et al. 5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis. Neuron. 2008; 60(4):582–589. doi:10.1016/j.neuron.2008.09.033

55. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM.Positional cloning of the mouse obese gene and its human homologue. Nature. 1995; 374(6521):425–432. doi:10.1038/372425a0

56. Zhang ZJ, Yao ZJ, Mou XD, Chen JF, Zhu RX, et al. Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent–induced weight gain. Zhonghua Yi XueZaZhi. 2003; 83(24):2119–2123. PMID: 14720418